Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Associations of Cardiovascular Risk Factors and Genetic Markers with Development of Arterial Hypertension in the Population of Mountain Shoriya

https://doi.org/10.20996/1819-6446-2018-14-5-678-686

Full Text:

Abstract

Aim. To study the combined effect of cardiovascular risk factors and genetic markers that encode the proteins of the main components of neurophysiological systems (renin-angiotensin-aldosterone, sympathetic-adrenal systems, endothelial dysfunction) on the development of arterial hypertension among the indigenous and non-indigenous population of Mountain Shoriya.

Material and methods. We performed a clinical and  epidemiological study  of the compactly settled population in the remote areas  of Mountain Shoriya. This region of middle mountains is situated in the south of Western Siberia. We examined 1409 subjects (901 subjects – the representatives of indigenous nationality [the Shors], 508 subjects – representatives of non-indigenous nationality [90% among them  were the representatives of the European ethnicity]). Hypertension was diagnosed according to the National Guidelines of the Russian Society of Cardiology/the Russian Medical Society on Arterial Hypertension (2010). All patients underwent clinical, laboratory and  instrumental investigation. Polymorphisms of genes  ACE (I/D, rs 4340), АGT (c.803T>C, rs699), AGTR1 (А1166С, rs5186), ADRB1 (с.145A>G, Ser49Gly, rs1801252), ADRA2B (I/D, rs 28365031), MTHFR (c.677С>Т, Ala222Val, rs1801133) and NOS3 (VNTR, 4b/4a) were tested using polymerase chain reaction.

Results. Cardiovascular risk factors  associated with hypertension in cohort  of Shorians: hypercholesterolemia [Odds Ratio (OR) 1.54,  low density lipoproteinemia (OR 1.48), violation of carbohydrate metabolism (OR 1.53), obesity (OR 2.25), including its abdominal type (OR 1.53), the family anamnesis of early cardiovascular diseases (OR 1.88)]  and  rs4340 polymorphisms of the  ACE gene  (OR 4.39), rs5186 of the  AGTR1 gene  (OR 10.02); in the cohort of the non-indigenous ethnos – hypercholesterolemia (OR 1.87), hypertriglyceridemia (OR 1.87), obesity (OR 2.75), abdominal obesity (OR 2.73), family anamnesis of early cardiovascular diseases (OR 2.48), the polymorphism rs5186 of the AGTR1 gene (OR 26.77). Genotype G/G ADRB1 gene was characterized by protective effect against hypertension in the Shorians.

Conclusion. Evaluation of the complex influence of clinical and genetic factors  on the development of hypertension in the population of Mountain Shoriya showed their comparable importance among the indigenous population and  the predominance of non-genetic factors  among the non-indigenous population.

About the Authors

T. A. Mulerova
Research Institute for Complex Issues of Cardiovascular Diseases; Novokuznetsk Institute for the Advancement of Doctors (branch of the Russian Medical Academy of Continuing Professional Education)
Russian Federation

Tatyana A. Mulerova – MD, PhD, Senior Researcher,  Laboratory of Epidemiology of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases; Associate Professor, Chair of Cardiology, Novokuznetsk Institute for the Advancement of Doctors (branch of the Russian Medical Academy of Continuing Professional Education).

Sosnoviy bulv. 6, Kemerovo,  650002; Stroiteley pr. 5, Novokuznetsk, 654006.

 

 



S. A. Maksimov
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation

Sergey A. Maksimov – MD, PhD, Leading Researcher,  Laboratory of Epidemiology of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases.

Sosnoviy bulv. 6, Kemerovo,  650002.

 



M. Yu. Ogarkov
Research Institute for Complex Issues of Cardiovascular Diseases; Novokuznetsk Institute for the Advancement of Doctors (branch of the Russian Medical Academy of Continuing Professional Education)
Russian Federation

Mikhail Yu. Ogarkov – MD, PhD, Professor, Head of Laboratory of Epidemiology of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases; Head of Chair of Cardiology, Novokuznetsk Institute for the Advancement of Doctors (branch of the Russian Medical Academy of Continuing Professional Education).

Sosnoviy bulv. 6, Kemerovo,  650002; Stroiteley pr. 5, Novokuznetsk, 654006.

 

 

 

 

 



O. V. Gruzdeva
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation

Olga V. Gruzdeva – MD, PhD, Head of Research Laboratory of Homeostasis, Department of Diagnostics of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases.

Sosnoviy bulv. 6, Kemerovo,  650002.

 



A. V. Ponasenko
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation

Anastasia V. Ponasenko – MD, PhD, Head of Laboratory of Genomic Medicine, Research Institute for Complex Issues of Cardiovascular Diseases.

Sosnoviy bulv. 6, Kemerovo,  650002.

 



V. N. Maksimov
Research Institute of Therapy and Preventive Medicine (branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences)
Russian Federation

Vladimir  N. Maksimov – MD, PhD, Head of Laboratory of Molecular Genetic Studies of Therapeutic Diseases, Research Institute of Therapy and Preventive Medicine (branch of the Federal Research Center – Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences).

Borisa Bogatkova ul. 175/1, Novosibirsk, 630089.

 



M. I. Voyevoda
Research Institute of Therapy and Preventive Medicine (branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences)
Russian Federation

Mikhail I. Voyevoda – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director of Research Institute of Therapy and Preventive Medicine (branch of the Federal Research Center – Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences).

Borisa Bogatkova ul. 175/1, Novosibirsk, 630089.

 



E. S. Filimonov
Novokuznetsk Institute for the Advancement of Doctors (branch of the Russian Medical Academy of Continuing Professional Education)
Russian Federation

Egor S. Filimonov – MD, Post-Graduate Student, Chair of Therapy, Novokuznetsk Institute for the Advancement of Doctors (branch of the Russian Medical Academy of Continuing Professional Education).

Stroiteley pr. 5, Novokuznetsk, 654006.

 



G. V. Artamonova
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation

Galina V. Artamonova – MD, PhD, Professor, Deputy Director for Science, Research Institute for Complex Issues of Cardiovascular Diseases.

Sosnoviy bulv. 6, Kemerovo,  650002.

 

 



References

1. Oganov R.G., Timofeeva T.N., Koltunov I.E. Epidemiology of hypertension in Russia. The results of the Federal monitoring 2003-2010. Cardiovascular Therapy and Prevention. 2011;10(1):8-12. (In Russ.).

2. Chazova I.E., Zhernakova Yu.V., Oschepkova E.V. The prevalence of risk factors for cardiovascular diseases in the Russian population of patients with arterial hypertension. Kardiologiia.2014;54(10):4-12 (In Russ.)

3. Singh M., Singh A.K., Pandey P. et al. Molecular genetics of essential hypertension. Clin Exp Hypertens. 2016;38(3):268-77. doi:10.3109/10641963.2015.1116543.

4. Markel A. L. Hypertensive disease: genetics, clinic, experiment. Russian Journal of Cardiology. 2017;150(10):133-39. (in Russ.).

5. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertеns. 2013;31:1281-357. doi:10.1097/HJH.0b013e328364ca4c.

6. Snapir A., Scheinin M., Groop L.C. et al. The insertion/deletion variation in the α2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in sib-pairs from families with type 2 diabetes. Cardiovasc Diabetol. 2003;24(2):15. doi:10.1016/S0735-1097(02)02702-X.

7. Lima J.J., Feng H., Duckworth L. et al. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism. 2007;6:757-65. doi:10.1016/j.metabol.2007.01.007

8. Salimi S., Firoozrai M., Nourmohammadi I. et al. Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with coronary artery disease in Iran. Indian J Med Res. 2006;124(6):683-688.

9. Barbarash O.L., Voevoda M.I., Artamonova G.V. Genetic determinants of arterial hypertension in two national cohorts of Mountain Shoria. Ter Arkhiv. 2017;89(9):68-77. (In Russ.).

10. Campbell N.R., Lackland D.T., Niebylski M.L. et al. World hypertension league committee; international society of hypertension executive committee. High blood pressure: why prevention and control are urgent and important: a 2014 fact sheet from the world hypertension league and the international society of hypertension. J Clin Hypertens (Greenwich). 2014;16(8):551-53. doi:10.1111/jch.12372.

11. Zdrojewski T., Wizner B., Więcek A. et al. Prevalence, awareness, and control of hypertension in elderly and very elderly in Poland: results of a cross-sectional representative survey. J Hypertens. 2016;34(3):532-8. doi:10.1097/HJH.0000000000000823.

12. Supiyev A., Kossumov A., Utepova L. et al. Prevalence, awareness, treatment and control of arterial hypertension in Astana, Kazakhstan. A cross-sectional study. Public Health. 2015;129(7):948-53. doi:10.1016/j.puhe.2015.02.020.

13. Kannel W. B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(1 Pt 2):3-10.

14. Mehri S., Mahjoub S., Hammami S., et al. Renin-angiotensin system polymorphisms in relation to hypertension status and obesity in a Tunisian population. Mol Biol Rep. 2012;39(4):4059-65. doi:10.1007/s11033-011-1187-2.

15. Zotova T.Y., Kubanova A.P., Azova M.M. Analysis of polymorphism of angiotensin system genes (ACE, AGTR1, and AGT) and gene ITGB3 in patients with arterial hypertension in combination with metabolic syndrome. Bull Exp Biol Med. 2016;161(3):334-8. doi:10.1007/s10517-016-3408-0.

16. Sun F., He N., Zhang K. et al. Association of ACE gene A2350G and I/D polymorphisms with essential hypertension in the northernmost province of China. Clin Exp Hypertens. 2018;40(1):32-8. doi:10.1080/10641963.2017.1291659.

17. Rana G., Yadav S., Joshi S., Saraswathy K.N. Association of DD genotype of angiotensin-converting enzyme gene (I/D) polymorphism with hypertension among a North Indian population. J Community Genet. 2018;9(1):51-5. doi:10.1007/s12687-017-0321-9.

18. Hussain M., Awan F.R., Gujjar A. et al. A case control association study of ACE gene polymorphism (I/D) with hypertension in Punjabi population from Faisalabad, Pakistan. Clin Exp Hypertens. 2018;40(2):186-91. doi:10.1080/10641963.2017.1356842.

19. Tchelougou D, Kologo JK, Karou SD, et al. Renin-angiotensin system genes polymorphisms and essential hypertension in Burkina Faso, West Africa. Int J Hypertens. 2015;2015:979631. doi:10.1155/2015/979631.

20. Al-Najai M., Muiya P., Tahir A.I. et al. Association of the angiotensinogen gene polymorphism with atherosclerosis and its risk traits in the Saudi population. BMC Cardiovasc Disord.2013;13:17. doi:10.1186/1471-2261-13-17.

21. Qian X., Guo D., Zhou H., et al. Interactions between PPARG and AGTR1 gene polymorphisms on the risk of hypertension in Chinese Han population. Genet Test Mol Biomarkers. 2018;22(2):90-7. doi:10.1089/gtmb.2017.0141.

22. Sudhir C., Rajiv N., Vishnubhatla S., et al. Association of Angiotensin II Type 1 Receptor (A1166C) Gene Polymorphism and Its Increased Expression in Essential Hypertension: A Case-Control Study. PLoS ONE. 2014; 9(7):e101502. doi:10.1371/journal.pone.0101502.

23. Ji L.D., Li J.Y., Yao B.B. et al. Are genetic polymorphisms in the renin-angiotensin-aldosterone system associated with essential hypertension? Evidence from genome-wide association studies. J Hum Hypertens. 2017;31(11):695-8. doi:10.1038/jhh.2017.29.

24. McNulty H., Strain J.J., Hughes C.F., Ward M. Riboflavin, MTHFR genotype and blood pressure: A personalized approach to prevention and treatment of hypertension. Mol Aspects Med. 2017;53:2-9. doi:10.1016/j.mam.2016.10.002.

25. Rashed L., Abdel Hay R., AlKaffas M. et al. Studying the association between methylenetetrahydrofolate reductase (MTHFR) 677 gene polymorphism, cardiovascular risk and lichen planus. J Oral Pathol Med. 2017;46(10):1023-9. doi:10.1111/jop.12588.

26. Ghogomu S.M., Ngolle N.E., Mouliom R.N., Asa B.F. Association between the MTHFR C677T gene polymorphism and essential hypertension in South West Cameroon. Genet Mol Res. 2016;15(1). doi:10.4238/gmr.15017462.

27. Tang Z., Xiao L., Wang J.Q., Zhang T. Analysis of metabolism-related indicators and MTHFR gene polymorphism in patients with H-type hypertension. Minerva Med. 2017;108(2):103-107. doi:10.23736/S0026-4806.16.04951-X.

28. Li W.X., Liao P., Hu C.Y. et al. Interactions of Methylenetetrahydrofolate Reductase Gene Polymorphisms, Folate, and Homocysteine on Blood Pressure in a Chinese Hypertensive Population. Clin Lab. 2017;63(4):817-25. doi:10.7754/Clin.Lab.2016.160918.

29. Amrani-Midoun A., Kiando S.R., Treard C. et al. The relationship between MTHFR C677T gene polymorphism and essential hypertension in a sample of an Algerian population of Oran city. Int J Cardiol. 2016;225:408-11. doi:10.1016/j.ijcard.2016.10.027


For citation:


Mulerova T.A., Maksimov S.A., Ogarkov M.Y., Gruzdeva O.V., Ponasenko A.V., Maksimov V.N., Voyevoda M.I., Filimonov E.S., Artamonova G.V. Associations of Cardiovascular Risk Factors and Genetic Markers with Development of Arterial Hypertension in the Population of Mountain Shoriya. Rational Pharmacotherapy in Cardiology. 2018;14(5):678-686. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-5-678-686

Views: 136


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)